23 completed, 1 withdrawn. 24 Phase 2.
By phase and status
Follow Simeprevir: new trials by email Literature Review of Simeprevir trials Research Report on Simeprevir
Trials (filtered) newest first · largest first
All 24 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive AL-335, Odalasvir (ODV), Simeprevir (SMV) - Hepatitis C, Chronic | Phase 2 | Completed | 33 | 2016-12-21 | 2019-09-11 |
Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection AL-335, Odalasvir, Simeprevir - Hepatitis C, Chronic | Phase 2 | Completed | 365 | 2016-11-09 | 2019-11-20 |
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir AL-335, Odalasvir (ODV), Simeprevir (SMV) - Chronic Hepatitis C | Phase 2 | Completed | 161 | 2015-10-31 | 2019-07-16 |
A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection Simeprevir (SMV), Ledipasvir (LDV), Sofosbuvir (SOF) - Hepatitis C, Chronic | Phase 2 | Completed | 41 | 2015-05-19 | 2019-03-28 |
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects PR4 + LDV/SOF + ASV 4 wk, PR4 + LDV/SOF + SMV 4 wk, PR4 + LDV/SOF + ASV 6 wk - Chronic Hepatitis C Infection | Phase 2 | Completed | 138 | 2015-05-15 | 2025-03-26 |
An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis. Simeprevir (SMV) 150 mg, Daclatasvir (DCV) 60 mg - Renal Impairment, End-stage Renal Disease | Phase 2 | Withdrawn | | 2015-05-01 | 2015-07-17 |
Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients Sofosbuvir + Simeprevir + Ribavirin - Chronic Hepatitis C Virus Infection | Phase 2 | Completed | 203 | 2015-04-01 | 2020-05-12 |
A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants Simeprevir, Daclatasvir - Hepatitis C, Chronic | Phase 2 | Completed | 106 | 2015-01-01 | 2017-03-16 |
Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects LDV/SOF+ASV, SOF+DCV+SMV, SOF+DCV+ASV - Chronic Hepatitis C Infection | Phase 2 | Completed | 18 | 2015-01-01 | 2016-03-01 |
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg - Hepatitis C Virus | Phase 2 | Completed | 68 | 2015-01-01 | 2017-03-01 |
An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection Simeprevir, Sofosbuvir - Hepatitis C | Phase 2 | Completed | 63 | 2014-12-01 | 2016-10-14 |
Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection Simeprevir, Sofosbuvir - Chronic Hepatitis C | Phase 2 | Completed | 30 | 2014-10-01 | 2016-02-24 |
An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease Simeprevir, Daclatasvir, Sofosbuvir - Hepatitis C, Chronic | Phase 2 | Completed | 40 | 2014-09-30 | 2025-02-04 |
An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant Simeprevir, Sofosbuvir, Ribavirin - Hepatitits C | Phase 2 | Completed | 46 | 2014-08-01 | 2016-11-11 |
A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation Simeprevir, Daclatasvir, Ribavirin - Hepatitis C, Chronic | Phase 2 | Completed | 35 | 2013-12-12 | 2018-11-21 |
Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) Samatasvir, Simeprevir, Ribavirin (RBV) - Chronic Hepatitis C Virus | Phase 2 | Completed | 143 | 2013-03-01 | 2015-04-23 |
A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus TMC647055, TMC435, Ritonavir - Chronic Hepatitis C | Phase 2 | Completed | 90 | 2012-10-01 | 2016-01-11 |
Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus Daclatasvir, Simeprevir, Ribavirin - Hepatitis C Virus | Phase 2 | Completed | 230 | 2012-07-01 | 2017-02-23 |
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients TMC435, PSI-7977 (GS7977), Ribavirin - Hepatitis C | Phase 2 | Completed | 168 | 2012-01-01 | 2015-02-09 |
A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment TMC435, Placebo, Peg-IFN-alfa-2a (P) - Hepatitis C | Phase 2 | Completed | 463 | 2009-10-01 | 2014-06-09 |
Showing 20 of 24. Sign in to see all of them.
Conditions studied
Hepatitis C, Chronic (12) · Hepatitis C (9) · Fibrosis (1) · Kidney Failure, Chronic (1) · Liver Cirrhosis (1) · Renal Insufficiency (1)
Sponsors
Janssen R&D Ireland (4) · Tibotec Pharmaceuticals, Ireland (4) · Janssen Research & Development, LLC (3) · Humanity and Health Research Centre (2) · Janssen Pharmaceutical K.K. (2) · Janssen-Cilag International NV (2) · Alios Biopharma Inc. (1) · Beni-Suef University (1) · Bristol-Myers Squibb (1) · Janssen Sciences Ireland UC (1) · Janssen Scientific Affairs, LLC (1) · Merck Sharp & Dohme LLC (1) · Peter J. Ruane, M.D. (1)
Countries
Germany (9) · Belgium (8) · United States (8) · France (6) · Spain (6) · Poland (5) · Canada (4) · United Kingdom (4) · New Zealand (3) · Australia (2) · Austria (2) · China (2) · Hungary (2) · Japan (2) · Norway (2)
Top investigators
George Lau (1) · George Lau, MD (1) · Peter J Ruane, MD (1)
Results publications
PMID 25164700, PMID 25445400, PMID 22024518, PMID 22885330, PMID 23907700, PMID 24005956, PMID 24184810, PMID 25078309, PMID 26453968, PMID 27790789, PMID 27878906, PMID 27896858, PMID 27917405, PMID 28135777, PMID 28295849, PMID 28569206, PMID 28971875, PMID 29274193, PMID 30598598, PMID 32270053, PMID 38587329
NIH funding
2014 (2), 2015 (2), 2008 (1), 2009 (1)